scholarly journals Impact of adjuvant chemotherapy on long-term employment of survivors of early-stage breast cancer

Cancer ◽  
2014 ◽  
Vol 120 (12) ◽  
pp. 1854-1862 ◽  
Author(s):  
Reshma Jagsi ◽  
Sarah T. Hawley ◽  
Paul Abrahamse ◽  
Yun Li ◽  
Nancy K. Janz ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Adjuvant Chemotherapy ◽  
Early Stage ◽  
Early Stage Breast Cancer

Incidence of long-term hair loss (LHL) following docetaxel (D)-containing non-anthracycline (A) adjuvant chemotherapy (Adj) of early stage breast cancer (ESB).

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. e12522-e12522
Author(s):  
John Crown ◽  
Janice Maria Walshe ◽  
David William Fennelly ◽  
Jessica-Clare Long ◽  
Josephine Ballot ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Adjuvant Chemotherapy ◽  
Hair Loss ◽  
Early Stage ◽  
Early Stage Breast Cancer

scholarly journals Can Chemotherapy-Related Acute Care Visits Be Accurately Identified in Administrative Data?

2018 ◽  
Vol 14 (1) ◽  
pp. e51-e58 ◽  
Author(s):  
Monika K. Krzyzanowska ◽  
Katherine Enright ◽  
Rahim Moineddin ◽  
Lingsong Yun ◽  
Melanie Powis ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Emergency Department ◽  
Adjuvant Chemotherapy ◽  
Acute Care ◽  
Administrative Data ◽  
Validation Cohort ◽  
Early Stage ◽  
Early Stage Breast Cancer ◽  
Algorithm Validation ◽  
Ed Visits

Purpose: There is increasing interest in using administrative data to examine treatment-related complications that lead to emergency department (ED) visits or hospitalizations (H). The purpose of this study was to evaluate the reliability of billing codes for identifying chemotherapy-related acute care visits (CRVs) among women with early-stage breast cancer. Materials and Methods: The cohort was identified by using deterministically linked health databases and consisted of women who were diagnosed with early-stage breast cancer who started adjuvant chemotherapy between 2007 and 2009 in Ontario, Canada. A random sample of 496 patient cases was chosen as the validation cohort. Sensitivity (SN) and specificity (SP) were calculated for three scenarios: chemotherapy-related ED visit, chemotherapy-related H, and febrile neutropenia (FN)–related visit. For FN-related visits, three definitions were considered: general, moderate, and strict. Results: The administrative cohort consisted of 8,359 patients, 43.4% of whom had at least one ED or H, including 1,496 women who had multiple visits that resulted in 6,293 unique visits. Of these, 73.1% were considered CRVs. The algorithm performed well in identifying CRVs that included H either from ED (SN, 90%; SP, 100%) or directly from home (SN, 91%; SP, 93%), but less well for ED visits that did not result in H (SN, 65%; SP, 80%). Depending on which FN algorithm was used, 4.8% to 24% of visits were considered related. The moderate FN algorithm provided the best tradeoff between SN (69% to 97%) and SP (83% to 98%). Conclusion: Administrative data can be valuable in evaluating chemotherapy-related serious events. Algorithm validation in other cohorts is needed.

Sign in / Sign up

Export Citation Format

Share Document